Abstract

An estimated 17,000 new cases of esophageal cancer will be diagnosed in the United States this year alone along with an estimated 16,000 deaths (1). Neoadjuvant chemotherapy with or without concurrent radiotherapy followed by surgery has emerged as a treatment of choice for locally-advanced esophageal cancer after several studies demonstrated a survival benefit of concurrent neoadjuvant chemoradiotherapy versus surgery alone (2).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call